Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Barclays analysts are bullish on Novo Nordisk (NYSE:NVO) stock ahead of the December release of pivotal clinical trial data ...

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

Novo Nordisk A/S shares slipped again on Tuesday, briefly erasing what was left of this year’s lofty gains, as concerns ...

Still, in the aftermath, Eli Lilly stock has dropped 4.8%. Novo Nordisk stock has shed 2.2%. Shares of Amgen, Pfizer and Roche have lost between 2% and 4%. Smaller biotech Structure Therapeutics has ...

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish ...

Over the last couple of years, Danish company Novo Nordisk (NYSE: NVO) has evolved from a relatively obscure pharmaceutical business to perhaps the biggest rising star in healthcare. The company's ...

I think that if you're an investor with a long-term time horizon, right now is a terrific opportunity to buy shares of Novo Nordisk. I see it as a compelling buy-and-hold stock, and believe that ...

Shares are trading at their lowest forward P/E multiples this year, thanks to a prolonged sell-off in the stock that's been going on since the late summer. As an investor in Novo Nordisk ...